DOCSLIB.ORG

Effect of Selective Estrogen Receptor Modulators on Cell Proliferation and Estrogen Receptor Activities in Normal Human Prostate Stromal and Epithelial Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Selective Estrogen Receptor Modulators on Cell Proliferation and Estrogen Receptor Activities in Normal Human Prostate Stromal and Epithelial Cells Prostate Cancer and Prostatic Diseases (2009) 12, 375–381 & 2009 Nature Publishing Group All rights reserved 1365-7852/09 $32.00 www.nature.com/pcan ORIGINAL ARTICLE Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells H Nomura, H Kawashima, S Masaki, TY Hosono, K Matsumura, S Tamada, T Tanaka and T Nakatani Department of Urology, Osaka City University Graduate School of Medicine, Asahimachi, Abenoku, Osaka, Japan We examined the effect of E2 and selective estrogen receptor modulators (SERMs) on the proliferation and estrogen receptor (ER) activities in normal human prostate cells. SERMs such as toremifene, raloxifene and tamoxifen suppressed the proliferation of prostate epithelial and stromal cells whereas anti-androgens did not. In prostate stromal cells, the transactivation activities of ER were enhanced by adding E2 and reduced remarkably by toremifene. The results indicate that the ER-mediated pathway plays a central role in the growth of normal prostate cells. Prostate Cancer and Prostatic Diseases (2009) 12, 375–381; doi:10.1038/pcan.2009.20; published online 26 May 2009 Keywords: selective estrogen receptor modulator (SERM); estrogen receptors a and b; normal prostate stromal cells; normal prostate epithelial cells Introduction investigated; the results indicate the possible involve- ment of estrogen receptors (ERs) in prostate cancer cell Although the most striking characteristic of the prostate proliferation.5,10 gland is its androgen dependence, estrogen and the BPH is the most common prostatic disease that will estrogen receptors have been reported to be involved affect many men as they age. One of the hypothesized in the development of the prostate gland and the pathogeneses of BPH is that the stromal hyperplasia is pathogenesis of prostatic diseases.1 Maternal estradiol, related to an enhanced estrogenic status after middle age, for example, stimulates squamous metaplasia within the with a decreased androgen level and an increased developing prostatic epithelium in a male offspring.2 conversion of adrenal androgens to estrogen by aroma- With regard to localized prostate cancer, expression tase.11 Recently, key studies on the role of estrogen in the levels of the estrogen receptor b (ERb) decline with pathogenesis of BPH have been carried out using normal increasing grade from prostatic intraepithelial neoplasia human prostate stromal and epithelial cells. King et al.12 through low to high Gleason scores, suggesting that ERb reported that an increased estrogen/androgen ratio is a putative tumor suppressor.2 In contrast, estrogens stimulated the proliferation of prostate stromal cells seem to induce prostate stromal cell proliferation; it is and enhanced the growth of prostate epithelial cells co- well known that the administration of estrogens com- cultured with stromal cells. Zhong et al.13 focused on bined with androgens has been used to induce BPH ERK, which was shown to be activated by estradiol with experimentally in dogs.2 the proliferation of prostate stromal cells. Since the discovery of the ERb,3 expression of estrogen While those investigations support that ERs a and b receptors a and b has been extensively studied using may directly modulate the prostatic cell growth, it is RT-PCR or immunohistochemical technique in several necessary to investigate whether the ERs in prostatic cells prostate cancer cell lines as well as in normal and are actually activated by ligands with the corresponding malignant prostatic tissues, those authors associating the transcription of the downstream genes causing changes expression of each estrogen receptor (ER) in various cells in cell proliferation. with its possible function and role.4–9 Effect of ligands Primary cultures of normal human prostatic epithelial and selective estrogen receptor modulators (SERMs) on and stromal cells are commercially available and have the growth of several prostate cancer cells has also been been used as useful models for the normal prostate epithelium and normal stroma in many studies. They exhibit limited lifespan with cellular senescence in Correspondence: Dr H Kawashima, Department of Urology, Osaka culture.14,15 In cultured prostatic stromal cells, mRNA City University Graduate School of Medicine, 1-4-3 Asahimachi, of androgen receptor (AR) is expressed,16–18 whereas Abenoku, Osaka 545-8585, Japan. reduced expression of AR protein in late passages has E-mail: [email protected] 18 Received 21 January 2009; revised 7 April 2009; accepted 8 April 2009; been reported. The commercially available prostatic published online 26 May 2009 epithelial cells possess the features of basal epithelia that Effect of SERMs on normal human prostate cells H Nomura et al 376 lack the expression of AR protein;15,19,20 those cells are Luciferase assay not fully differentiated to be the secretory epithelial The luciferase assay was carried out using Dual- cells.15 luciferase reporter assay system (Promega) according to Currently, we show for the first time that endogenous the methods recommended by the manufacturer. In estrogen receptors were activated by estrogen in the short, cells were rinsed with PBS and harvested follow- primary cultures of normal human prostate cells, and ing the addition of 250 ml of the lysis buffer per well by that their activities were modulated by selective estrogen scraping with a rubber policeman. The cells were receptor modulators (SERMs) accompanied by changes subjected to two freeze/thaw cycles to accomplish in cell growth. complete lysis, and the lysate was cleaned by centrifuga- tion for 1 min. After preparation of the Luciferase Assay Reagent II and the Stop & Glo Reagent supplied in the kit, 20 ml of the cell lysate was added to 100 ml of the Materials and methods Luciferase Assay Reagent II in a luminometer tube and mixed. The firefly luciferase activity was measured using Materials a luminometer with the program of a 2-s premeasure- The normal human prostate stromal and epithelial cells, ment delay followed by a 10-s measurement period for PrSC and PrEC, were purchased from LonzaWalkersville each reporter assay. Then, 100 ml of Stop & Glo Reagent (Walkersville, MD, USA). The prostate cancer cell line, was further added and the second measurement of the LNCaP cells, was purchased from American Type renilla luciferase activity was performed. The results of Culture Collection (Rockville, MD, USA). Dual-luciferase the luciferase assay were normalized using the activity of reporter assay system was obtained from Promega the renilla expression vector pRL-TK co-transfected (Madison, WI, USA) and FuGENE 6 Transfecton Reagent together with the reporter plasmid. from Roche (Mannheim, Germany). A reporter gene for ER, pGL3-ERE-X3tK luciferase (pERE-luc), was a gener- ous gift from Dr. Shigeaki Kato, Tokyo University, Tokyo, Cell-proliferation assay Japan. An anti-androgen, flutamide and an anti-estrogen, The cell proliferation was measured using the water- toremifene, were generous gifts from Nippon Kayaku soluble tetrazolium salt assay system (WST-1 Cell Corp. (Tokyo, Japan). Raloxifene, tamoxifen, genistein Proliferation System: TaKaRa Bio, Otsu, Shiga, Japan). and 5a-dihydrotestosterone (DHT) were purchased from In short, PrSC or PrEC cells were seeded at 1 Â105 cells Sigma-Aldrich (Saint Louis, MO, USA) and a pure anti- per well onto 6-well plates and incubated for 24 h. Then, estrogen faslodex (ICI182,780) was from Tocris (Ellisville, ligands were added and the cells were further grown for MO, USA). b-Estradiol and bisphenol A (BPA) were from 48 h and subjected to WST-1 assay. WST-1 reagent was Wako Pure Chemical (Osaka, Japan). added to each well, cells were incubated at 37 1C for 2 h and the absorbance was measured at 450 nM. Cell culture and transient transfection TUNEL assay The normal human prostate stromal and epithelial cells, The TUNEL (terminal deoxynucleotidyl transferase- PrSC and PrEC, were maintained in Prostate Stromal mediated dUTP nick end labeling) assay was carried Cell Growth Medium (PrSCGM) supplemented with out using APO-DIRECT Kit (BD Biosciences, San Jose, PrSCGM SingleQuots (Lonza) and Prostate Epithelial CA, USA) according to the manufacturer’s instruction. Cell Growth Medium (PrEGM) supplemented with After labeling DNA breaks with FITC-dUTP, samples PrEGM SingleQuots (Lonza), respectively according were subjected to flow cytometric analysis using a FACS to the manufacturer’s instruction. LNCaP cells were Calibur flow cytometer (Becton Dickinson, San Jose, CA, maintained in RPMI-1640 supplemented with 10% USA). FCS, 100 U mlÀ1 of penicillin and 100 mgmlÀ1 of streptomycin. Cells (2 Â 105) for LNCaP or 1 Â105 cells for PrEC and Statistical analysis PrSC per each well were plated onto six-well culture Differences between treatment groups were assessed by plates, incubated for 24 h and used for assay. The PrEC Student’s paired t-test. Po0.05 was considered as and PrSC plated onto six-well culture plates were statistically significant. transiently transfected using FuGENE transfection re- agent (Roche) with 1.05 mg of DNA mixture containing pERE-luc reporter (1 mg) and pRL-TK (50 ng) in accor- dance with the manufacturer’s instructions and further Results grown for 24 h in PrECGM for PrEC or in PrSCGM for Effect of hormones and an anti-estrogen toremifene on PrSC. LNCaP cells plated onto six-well culture plates were transiently transfected using FuGENE transfection proliferation of normal human prostate epithelial and reagent with pERE-luc (1 mg) and pRL-TK (50 ng) stromal cells according to the manufacturer’s instruction and further To access the importance of the estrogenic signaling in grown for 24 h in RPMI-1640 with 10% fetal bovine normal human prostate cells, DHT, estradiol (E2), serum dialyzed (10 000 MW cutoff, Sigma), penicillin and estrogenic chemicals and an anti-estrogen were admini- streptomycin. Then, b-estradiol or SERM was added to strated to prostate epithelial and stromal cells. As a the final concentration at 10 nM for b-estradiol or at 10 mM control, hormone-dependent prostate cancer cells, for SERM, and cells were further cultured for another LNCaP, were used.
Load more

Recommended publications
  • Prospective Study on Gynaecological Effects of Two Antioestrogens Tamoxifen and Toremifene in Postmenopausal Women
    British Journal of Cancer (2001) 84(7), 897–902 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2001.1703, available online at http://www.idealibrary.com on http://www.bjcancer.com Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women MB Marttunen1, B Cacciatore1, P Hietanen2, S Pyrhönen2, A Tiitinen1, T Wahlström3 and O Ylikorkala1 1Departments of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland; 2Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029 HYKS, Finland; 3Department of Pathology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland Summary To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment. The mean (±SD) follow-up time was 2.3 ± 0.8 years. 35% of the patients complained of vasomotor symptoms before the start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and toremifene (62.7%).
    [Show full text]
  • P53 and PTEN Expression Contribute to the Inhibition of EGFR Downstream Signaling Pathway by Cetuximab
    Cancer Gene Therapy (2009) 16, 498–507 r 2009 Nature Publishing Group All rights reserved 0929-1903/09 $32.00 www.nature.com/cgt ORIGINAL ARTICLE P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab S Bouali1, A-S Chre´tien1, C Ramacci1, M Rouyer1, S Marchal2, T Galenne3, P Juin3, P Becuwe4 and J-L Merlin1 1Centre Alexis Vautrin, Unite´ de Biologie des Tumeurs, EA ‘‘Predicther’’ Nancy Universite´, Vandœuvre-le`s- Nancy cedex, France; 2Centre Alexis Vautrin, CRAN UMR 7039 CNRS-UHP-INPL, Vandœuvre-le`s-Nancy cedex, France; 3INSERM U601, CHU de Nantes, Institut de Biologie, Nantes, France and 4Laboratoire de Biologie Cellulaire, Faculte´ des Sciences, EA ‘‘Predicther’’ Nancy Universite´, Vandœuvre-le`s-Nancy, France Cetuximab (Erbitux) is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody whose activity is related to the inhibition of EGFR downstream signaling pathways. P53 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) have been reported to control the functionality of PI3K/AKT signaling. In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations. Signaling phosphoproteins expression was analyzed using Bio-Plex phosphoprotein array and western blot. Apoptosis induction was evaluated from BAX expression, caspase-3 activation and DNA fragmentation analyses. The results presented show that p53 and pten gene transfer additionally mediated cell growth inhibition and apoptosis induction by restoral of signaling functionality, which enabled the control of PI3K/AKT and MAPKinase signaling pathways by cetuximab in PC3 cells.
    [Show full text]
  • Indirect Antitumor Effects of Bisphosphonates on Prostatic Lncap Cells Co-Cultured with Bone Cells
    ANTICANCER RESEARCH 29: 1089-1094 (2009) Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells TOMOAKI TANAKA, HIDENORI KAWASHIMA, KEIKO OHNISHI, KENTARO MATSUMURA, RIKIO YOSHIMURA, MASAHIDE MATSUYAMA, KATSUYUKI KURATSUKURI and TATSUYA NAKATANI Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan Abstract. Bisphosphonates are strong inhibitors of effectively inhibit bone absorption are available for osteoclastic bone resorption in both benign and malignant reducing the risk of skeletal complications in bone bone diseases. The nitrogen-containing bisphosphonates metastases of prostate cancer as well as those of other solid (N-BPs) have strong cytotoxicity via inhibition of protein tumors characterized by osteoclastic lesions. prenylation in the mevalonate pathway, and also demonstrate Bisphosphonates are potent inhibitors of osteoclast activity direct cytostatic and proapoptotic effects on prostate cancer and survival, thereby reducing osteoclast-mediated bone cells. We confirmed the usefulness of a co-culture system absorption (1, 4-6). The chemical structure of bisphosphonates comprised of prostatic LNCaP cells, ST2 cells (mouse- contributes to their mechanism of action: Non-nitrogen- derived osteoblasts) and MLC-6 cells (mouse-derived containing compounds (e.g. etidronate, clodronate) are osteoclasts) in vitro. N-BPs (pamidronate and zoledronic metabolized to cytotoxic analogues of ATP (7), while newer acid) inhibited both androgen receptor transactivation and nitrogen-containing bisphosphonates (N-BPs; pamidronate, tumor cell proliferation by suppressing the activities of both ibandronate, zoledronic acid) have strong cytotoxic effects on osteoclasts and osteoblasts with low-dose exposure. This cells via inhibition of protein prenylation in the mevalonate indirect inhibition of prostate cancer cells via bone cells pathway (8, 9).
    [Show full text]
  • Ribociclib (LEE011)
    Clinical Development Ribociclib (LEE011) Oncology Clinical Protocol CLEE011G2301 (EarLEE-1) / NCT03078751 An open label, multi-center protocol for U.S. patients enrolled in a study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2- negative, high risk early breast cancer Authors Document type Amended Protocol Version EUDRACT number 2014-001795-53 Version number 02 (Clean) Development phase II Document status Final Release date 17-Apr-2018 Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Template version 22-Jul-2016 Novartis Confidential Page 2 Amended Protocol Version 02 (Clean) Protocol No. CLEE011G2301 Table of contents Table of contents ................................................................................................................. 2 List of tables ........................................................................................................................ 5 List of abbreviations ............................................................................................................ 6 Glossary of terms ................................................................................................................. 9 Protocol summary .............................................................................................................. 10 Amendment 2 (17-Apr-2018) ............................................................................................ 14
    [Show full text]
  • Prostate Cancer Stromal Cells and Lncap Cells Coordinately Activate
    Endocrine-Related Cancer (2009) 16 1139–1155 Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone Atsushi Mizokami, Eitetsu Koh, Kouji Izumi, Kazutaka Narimoto, Masashi Takeda, Seijiro Honma1, Jinlu Dai 2, Evan T Keller 2 and Mikio Namiki Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa City 920-8640, Japan 1Teikoku Hormone MFG. Co., 1604 Shimosakunobe, Takatsu-ku, Kawasaki, Kanagawa 213, Japan 2Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan, USA (Correspondence should be addressed to A Mizokami; Email: [email protected]) Abstract One of the mechanisms through which advanced prostate cancer (PCa) usually relapses after androgen deprivation therapy (ADT) is the adaptation to residual androgens in PCa tissue. It has been observed that androgen biosynthesis in PCa tissue plays an important role in this adaptation. In the present study, we investigated how stromal cells affect adrenal androgen dehydroepian- drosterone (DHEA) metabolism in androgen-sensitive PCa LNCaP cells. DHEA alone had little effect on prostate-specific antigen (PSA) promoter activity and the proliferation of LNCaP cells. However, the addition of prostate stromal cells or PCa-derived stromal cells (PCaSC) increased DHEA-induced PSA promoter activity via androgen receptor activation in the LNCaP cells. Moreover, PCaSC stimulated the proliferation of LNCaP cells under physiological concentrations of DHEA. Biosynthesis of testosterone or dihydrotestosterone from DHEA in stromal cells and LNCaP cells was involved in this stimulation of LNCaP cell proliferation. Androgen biosynthesis from DHEA depended upon the activity of various steroidogenic enzymes present in stromal cells.
    [Show full text]
  • Toremifene (Fareston)
    Clinical Policy: Toremifene (Fareston) Reference Number: PA.CP.PMN.126 Effective Date: 10.17.18 Last Review Date: 04.17.19 Revision Log Description Toremifene (Fareston®) is an estrogen agonist/antagonist. FDA Approved Indication(s) Fareston is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with PA Health & Wellness® that Fareston is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Breast Cancer (must meet all): 1. Diagnosis of recurrent or metastatic breast cancer; 2. Prescribed by or in consultation with an oncologist; 3. Failure of a 1-month trial of tamoxifen at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 4. Failure of a 1-month trial of an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced (see Appendix B); 5. Request meets one of the following (a or b): a. Dose does not exceed 60 mg per day (1 tablet/day); b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Approval duration: 12 months B. Soft Tissue Sarcoma - Desmoid Tumors (off-label) (must meet all): 1. Diagnosis of desmoid tumor or aggressive fibromatosis; 2. Prescribed by or in consultation with an oncologist; 3.
    [Show full text]
  • Cell Line Lncap'
    ICANCER RESEARCH58. 76-83. January 1. 1998J Caspase-7 Is Activated during Lovastatin-induced Apoptosis of the Prostate Cancer Cell Line LNCaP' Marco Marcelli,2 Glenn R. Cunningham, S. Joe Haidacher, Sebastian J. Padayatty, Lydia Sturgis, Carolina Kagan, and Larry Denner Departments of Medicine (M. M.. G. R. C., S. J. H.. S. f. P.1 and Cell Biology [M. M., G. R. C.], Veterans Affairs Medical Center and Baylor College of Medicine, Department of Cell Biology (L S., C K., L DI, Texas Biotechnology C'orporation, Houston, Texas 77030 ABSTRACT androgen-dependent and androgen-independent cells even before therapy (4). The initial response following androgen ablation is The goals of this work were to establish a reproducible and effective thought to be due to the induction of apoptosis of androgen-dependent model of apoptosis in a cell line derived from advanced prostate cancer prostate cancer cells (5). Because androgen-independent cells are and to study the role of the caspase family of proteases in mediating insensitive to androgen ablation, they remain alive even in the absence apoptosis in this system. The study involved the use of the prostate cancer cell line LNCaP. Apoptosis was induced using the hydroxymethyl glutaryl of androgens (6). Hence, after the initial response to androgen ablation CoA reductase inhibitor, lovastatin, and was evaluated by agarose gel due to the death of androgen-dependent cells, the tumor progresses to electrophoresis of genomic DNA, morphological criteria, and terminal an androgen-independent state, and the patient is no longer curable deoxynucleotidyl traasferase-mediated nick end labeling. Caspases were (7).
    [Show full text]
  • Effects of Toremifene, a Selective Estrogen Receptor Modulator, On
    ISSN 2472-1972 Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects Ferdinand Roelfsema,1 Rebecca J. Yang,2 Paul Y. Takahashi,3 Dana Erickson,4 Cyril Y. Bowers,5 and Johannes D. Veldhuis2 1Department of Internal Medicine, Section of Endocrinology and Metabolism, Leiden University Medical Center, 2333 ZA Leiden, Netherlands; 2Endocrine Research Unit, Mayo School of Graduate Medical Education, Center for Translational Science Activities, Mayo Clinic, Rochester, Minnesota 55905; 3Department of Primary Care Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905; 4Department of Endocrinology, Mayo Clinic, Rochester, Minnesota 55905; and 5Department of Internal Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112 Context: Estrogens amplify spontaneous and stimulated growth hormone (GH) secretion, whereas they diminish GH-dependent insulin-like growth factor (IGF)-I in a dose-dependent manner. Selective es- trogen receptor modulators (SERMs), including tamoxifen and toremifene, are widely adjunctively used in breast and prostate cancer. Although some endocrine effects of tamoxifen are known, few data are available for toremifene. Objective: To explore sex-dependent effects of toremifene on spontaneous 10-hour overnight GH se- cretion, followed by GH-releasing hormone–ghrelin stimulation. Additionally, effects on IGF-I, its binding proteins, and sex hormone–binding globulin (SHBG) were quantified. Participants and Design: Twenty men and 20 women, within an allowableagerangeof50to80years, volunteered for this double-blind, placebo-controlled prospective crossover study. Ten-minute blood sampling was done for 10 hours overnight and then for 2 hours after combined GH-releasing hormone–ghrelin injection. Main Outcome Measures: Pulsatile GH and stimulated GH secretion, and fasting levels of IGF-I, IGF- binding protein (IGFBP)1, IGFBP3, and SHBG.
    [Show full text]
  • On the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes
    International Journal of Molecular Sciences Article The Impact of Ang-(1-9) and Ang-(3-7) on the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes Kamila Domi ´nska 1,* , Karolina Kowalska 2 , Kinga Anna Urbanek 2 , Dominika Ewa Habrowska-Górczy ´nska 2 , Tomasz Och˛edalski 1 and Agnieszka Wanda Piastowska Ciesielska 2 1 Department of Comparative Endocrinology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland; [email protected] 2 Department of Cell Cultures and Genomic Analysis, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland; [email protected] (K.K.); [email protected] (K.A.U.); [email protected] (D.E.H.-G.); [email protected] (A.W.P.C.) * Correspondence: [email protected] Received: 12 July 2020; Accepted: 26 August 2020; Published: 28 August 2020 Abstract: The local renin–angiotensin system (RAS) plays an important role in the pathophysiology of the prostate, including cancer development and progression. The Ang-(1-9) and Ang-(3-7) are the less known active peptides of RAS. This study examines the influence of these two peptide hormones on the metabolic activity, proliferation and migration of prostate cancer cells. Significant changes in MTT dye reduction were observed depending on the type of angiotensin and its concentration as well as time of incubation. Ang-(1-9) did not regulate the 2D cell division of either prostate cancer lines however, it reduced the size of LNCaP colonies formed in soft agar, maybe through down-regulation of the HIF1a gene.
    [Show full text]
  • Active Estrogen Synthesis and Its Function in Prostate Cancer-Derived Stromal Cells
    ANTICANCER RESEARCH 35: 221-228 (2015) Active Estrogen Synthesis and its Function in Prostate Cancer-derived Stromal Cells KAZUAKI MACHIOKA1, ATSUSHI MIZOKAMI1, YURI YAMAGUCHI2, KOUJI IZUMI1, SHINICHI HAYASHI3 and MIKIO NAMIKI1 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan; 2Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; 3Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Japan Abstract. Background: It remains unclear whether estrogen Castration-naïve prostate cancer (PCa) develops into is produced in prostate cancer (PCa) and how it functions in castration-resistant prostate cancer (CRPC) during androgen PCa. Materials and Methods: To examine the production of deprivation therapy (ADT) by various mechanisms. estrogen in PCa cells, the concentration of estrogen in the Especially, the androgen receptor (AR) signaling axis plays a medium in which LNCaP cells and PCa-derived stromal cells key role in this specific development. PCa cells mainly adapt (PCaSC) were co-cultured, was measured by liquid themselves to the environment of lower androgen chromatography-mass spectrometry/mass spectrometry (LC- concentrations and change into androgen-hypersensitive cells MS/MS), while aromatase (CYP19) mRNA expression was or androgen-independent cells. Androgens of adrenal origin confirmed by real-time polymerase chain reaction (RT-PCR) and their metabolites synthesized in the microenvironment in methods. To verify whether estrogen is synthesized from an intracrine/paracrine fashion act on surviving PCa cells and testosterone in PCaSC functions, PCaSC were co-cultured secrete prostate specific antigen (PSA). Therefore, new with breast cancer MCF-7-E10 cells, which were stably- recently developed medicines, abiraterone acetate that transfected with ERE-GFP, in the presence of testosterone.
    [Show full text]
  • Cell Adhesion and Chemotaxis in Prostate Cancer Metastasis to Bone: a Minireview
    Prostate Cancer and Prostatic Diseases (2000) 3, 6±12 ß 2000 Macmillan Publishers Ltd All rights reserved 1365±7852/00 $15.00 www.nature.com/pcan Review Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview CR Cooper1* & KJ Pienta1 1University of Michigan Comprehensive Cancer Center, Department of Internal Medicine, Ann Arbor, MI 48109, USA Bone metastasis is a common phenomenon in patients with advanced prostate cancer. The molecular and cellular mechanisms involved in this process are not well understood. Past reviews on this subject primarily focused on prostate tumor growth in the bone marrow and the effects this growth has on bone homeostasis (ie osteoblastic and osteolytic). Cell chemotaxis and adhesion are also important for site-speci®c metastasis. In this review we have focused on chemotactic and cell adhesion molecules potentially involved in prostate cancer metastasis to bone. In addition, recently developed animal models for prostate cancer metastasis to bone are discussed. Prostate Cancer and Prostatic Diseases (2000) 3, 6±12. Keywords: cell adhesion molecules; cytokines; human bone marrow endothelial cells; chemoattractants; prostate cancer cells Introduction cells.7 The inactivation of parathyroid hormone-related protein (PTH-rp) by prostate-speci®c antigen may pro- Prostate cancer bone metastasis is a major clinical prob- mote the osteoblastic reaction seen in prostate cancer lem and is commonly associated with intractable pain, patients. Yoneda has proposed that the minor osteolytic pathological
    [Show full text]
  • A Novel Anti-Androgen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth in Vitro and in Vivo
    Author Manuscript Published OnlineFirst on March 14, 2013; DOI: 10.1158/1535-7163.MCT-12-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A novel anti-androgen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Hidetoshi Kuruma1, Hiroaki Matsumoto1, Masaki Shiota1, Jennifer Bishop, Francois Lamoureux1, Christian Thomas1, David Briere2, Gerrit Los2, Martin Gleave1, Andrea Fanjul2 and Amina Zoubeidi1 1The Vancouver Prostate Centre, 2660 Oak Street, Vancouver, BC, Canada, V6H 3Z6 2Pfizer Oncology Research Unit, Worldwide Research & Development, 10646 Science Center Drive, San Diego, California, United States, 92121. Running Title: Efficacy of Compound 30 in MDV3100-resistant prostate cancer Key words: Castration-resistant prostate cancer, anti-androgen, MDV3100, Compound 30, androgen receptor, MR49F Financial support: Pfizer Global Research & Development (United States) and the Prostate Cancer Foundation USA (A. Zoubeidi) Corresponding author: Amina Zoubeidi, Ph.D. The Vancouver Prostate Centre, Department of Urologic Science University of British Columbia: 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada. [email protected] Disclosure: A. Fanjul, D. Briere and G. Los are employee of Pfizer. The other authors disclosed no potential conflicts of interest. Manuscript Type: Chemical (Small Molecule) Discovery and Clinical Development Total number of figures: 5 Word Count: 4,937 1 Downloaded from mct.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 14, 2013; DOI: 10.1158/1535-7163.MCT-12-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]